Table 3.
Characteristics of wild-type patients harboring NTRK fusions.
| Patients (#1–#5) | #1 | #2 | #3 | #4 | #5 |
|---|---|---|---|---|---|
| Age (years) | 44 | 45 | 65 | 61 | 43 |
| Sex | F | M | F | F | M |
| Location | Rectum | Duodenum | Stomach | Jejunum | Rectum |
| Mitotic rate (no. of mitoses/50 HPFs * | 17 | 1 | 70 | 12 | 0 |
| Size (cm) | 2.8 | 1.7 | 17.0 | 3.9 | 11.0 |
| Surgery (yes or no) | yes | yes | yes | yes | yes |
| Follow-up period (years) | 11 | 6 | 8 | 4 | 3 |
| NTRK fusion by FISH | NRTK1 | NRTK3 | NRTK1 | NRTK1 | NTRK3 |
| Imatinib | No | No | Adjuvant | Adjuvant | No |
| Disease/survival status | DDP | NED | DDP | NED | NED |
NTRK: neurotrophic tyrosine receptor kinase; FISH: fluorescence in situ hybridization; HPFs: high-power fields; * per 50 HPFs is a total of 5 mm2; DDP: dead due to disease progression; NED: no evidence of disease. # Number of patient.